期刊文献+

肺癌患者血清铁及铁蛋白水平的变化及其与炎症的相关性 被引量:5

Change of serum iron and ferritin levels in patients with lung cancer and their correlation with inflammation
原文传递
导出
摘要 目的分析肺癌患者血清铁以及铁蛋白水平的变化及其与炎症的相关性。方法选取2014年1月至2018年6月就诊于山西省肿瘤医院的147例初诊原发性肺癌患者作为观察组,并选取同期进行健康体检的135例健康人员作为对照组,分析两组患者的血清铁及铁蛋白水平,并对其进行血清铁及铁蛋白水平与炎症的相关性分析。结果观察组非小细胞肺癌Ⅰ~Ⅲ期与Ⅳ期患者血清铁及铁蛋白水平低于对照组(P<0.05),观察组非小细胞肺癌Ⅰ~Ⅲ期患者血清铁水平高于非小细胞肺癌Ⅳ期患者(P<0.05),血清铁蛋白水平低于非小细胞肺癌Ⅳ期患者(P<0.05)。观察组小细胞肺癌局限期患者血清铁水平高于对照组,而小细胞肺癌广泛期患者血清铁水平低于对照组(P<0.05);观察组小细胞肺癌局限期与广泛期患者铁蛋白水平低于对照组,且小细胞肺癌局限期患者铁蛋白水平低于小细胞肺癌广泛期患者(P<0.05)。肺癌患者血清铁水平与C反应蛋白(CRP)水平呈负相关关系,血清铁蛋白水平与CRP水平呈正相关关系。结论晚期肺癌患者血清铁水平低,铁蛋白水平高,肺癌患者血清铁及血清铁蛋白水平呈动态变化规律,其炎症起调节作用。 Objective To analyze the changes of serum iron and ferritin levels in patients with lung cancer and their correlation with inflammation.Methods One hundred and forty-seven patients with newly diagnosed primary lung cancer who were admitted to Shanxi Cancer Hospital from January 2014 to June 2018 were enrolled as the observations group,and 135 healthy people who were in hospital for physical examination at the same time were selected as the control group.The serum iron levels and ferritin levels in the two groups were analyzed,and the correlation analysis between serum iron,ferritin and inflammation was performed.Results The levels of serum iron and ferritin in patients with stage I-III and IV of non-small cell lung cancer(NSCLC)in observation group were lower than those in control group(P<0.05).In the observation group,the serum iron level in patients with stage I-III of NSCLC was higher than that in patients with stage IV of NSCLC(P<0.05),and the serum ferritin level was lower than that in patients with stage IV of NSCLC(P<0.05).The level of serum iron in patients with limited stage of small cell lung cancer(SCLC)in observation group was higher than that in control group,while the serum ferritin level in patients with extensive stage of SCLC in the observation group was lower than that in the control group(P<0.05).The level of ferritin in patients with limited and extensive stage of SCLC in observation group was lower than that in control group,and the level of ferritin in patients with limited stage of SCLC was lower than that in patients with extensive stage of SCLC(P<0.05).In lung cancer patients,serum iron level was negatively correlated with C-reactive protein(CRP)level,while serum ferritin level was positively correlated with CRP level.Conclusions In patients with advanced lung cancer,serum iron levels are low and ferritin levels are high.Serum iron and serum ferritin levels in lung cancer patients change in dynamic patterns,in which inflammation plays a regulatory role.
作者 郭毅 郭伟 Guo Yi;Guo Wei(Department of Respiratory,Shanxi Cancer Hospital,Taiyuan 030013,China)
出处 《中国实用医刊》 2019年第23期30-32,共3页 Chinese Journal of Practical Medicine
关键词 血清铁 铁蛋白 肺癌患者 炎症 Serum iron Ferritin Lung cancer patients Inflammation
  • 相关文献

参考文献5

二级参考文献78

  • 1Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.J Clin Oncol, 2002, 20(24): 4665-4672.
  • 2Siu LL, Shepherd FA, Murray N, et al. Influence of age on the treatment of limited-stage small-cell lung cancer.J Clin Oncol, 1996, 14(3): 821-828.
  • 3Jara c, Gomez-Aldaravi JL, Tirado R, et al. Small-cell lung cancer in the elderly-is age of patient a relevant factor? Acta Oncol, 1999, 38(6): 781-786.
  • 4Noguchi T, Mochizuki H, Yamazaki M, et al. A retrospective analysis of clinical outcomes of patients older than or equal to 80 years with small cell lung cancer.J Thora Oncol, 2010, 5(7): 1081-1087.
  • 5Caprario LC, Kent DM, Trikalinos TA, et al. Determinants of chemotherapy administration and effects of chemotherapy on survival in elderly patients with small cell lung cancer (SCLC): A SEER-medicare analysis. J Clin Oncol, 2011, 29(15 S): 7083 [abstract].
  • 6Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev, 2011, 37(2): 143-150.
  • 7Von Pawel J, Gatzemeier U, PujolJL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.J Clin Oncol, 2001, 19(6): 1743-1749.
  • 8Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol, 2007, 25 (15 ) : 2086-2092.
  • 9O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.J Clin Oncol, 2006, 24(34): 5441-5447.
  • 10von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 1999, 17(2): 658-667.

共引文献185

同被引文献37

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部